BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmad SM, Borch TH, Hansen M, Andersen MH. PD-L1-specific T cells. Cancer Immunol Immunother 2016;65:797-804. [DOI: 10.1007/s00262-015-1783-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Zou Q, Chen YF, Zheng XQ, Ye SF, Xu BY, Liu YX, Zeng HH. Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression. J Zhejiang Univ Sci B 2018;19:689-98. [PMID: 30178635 DOI: 10.1631/jzus.B1700219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Liu S, Liu F, Zhou Y, Jin B, Sun Q, Guo S. Immunosuppressive Property of MSCs Mediated by Cell Surface Receptors. Front Immunol 2020;11:1076. [PMID: 32849489 DOI: 10.3389/fimmu.2020.01076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
3 Liu Y, Lu Y, Zhu X, Li C, Yan M, Pan J, Ma G. Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy. Biomaterials 2020;242:119933. [DOI: 10.1016/j.biomaterials.2020.119933] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
4 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 2017;66:551-64. [DOI: 10.1007/s00262-017-1954-6] [Cited by in Crossref: 162] [Cited by in F6Publishing: 163] [Article Influence: 32.4] [Reference Citation Analysis]
6 Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med 2021;27:2212-23. [PMID: 34887574 DOI: 10.1038/s41591-021-01544-x] [Reference Citation Analysis]
7 Li Z, Li Y, Gao J, Fu Y, Hua P, Jing Y, Cai M, Wang H, Tong T. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sci 2021;273:119150. [PMID: 33662426 DOI: 10.1016/j.lfs.2021.119150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Pan J, Zeng W, Jia J, Shi Y, Wang D, Dong J, Fang Z, He J, Yang X, Zhang R, He M, Huang M, Fu B, Zhong B, Liu H. A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice. Vaccines (Basel) 2022;10:1092. [PMID: 35891256 DOI: 10.3390/vaccines10071092] [Reference Citation Analysis]
9 Ehlerding EB, England CG, McNeel DG, Cai W. Molecular Imaging of Immunotherapy Targets in Cancer. J Nucl Med 2016;57:1487-92. [PMID: 27469363 DOI: 10.2967/jnumed.116.177493] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
10 Yan M, Liu Y, Zhu X, Wang X, Liu L, Sun H, Wang C, Kong D, Ma G. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity. ACS Appl Mater Interfaces 2019;11:1876-85. [PMID: 30582788 DOI: 10.1021/acsami.8b18751] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 17.7] [Reference Citation Analysis]
11 Syeda MZ, Hong T, Zhang M, Han Y, Zhu X, Ying S, Tang L. A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy. Nano Res . [DOI: 10.1007/s12274-022-4598-6] [Reference Citation Analysis]
12 Zheng A, Li F, Chen F, Zuo J, Wang L, Wang Y, Chen S, Xiao B, Tao Z. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. Oncol Rep 2019;41:2833-43. [PMID: 30864729 DOI: 10.3892/or.2019.7053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Ødum N. Anti-regulatory T cells are natural regulatory effector T cells. Cell Stress 2019;3:310-1. [PMID: 31680691 DOI: 10.15698/cst2019.10.199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Qian B, Xue L, Qi X, Bai Y, Wu Y. Gene networks and toxicity/detoxification pathways in juvenile largemouth bass (Micropterus salmoides) liver induced by acute lead stress. Genomics 2020;112:20-31. [DOI: 10.1016/j.ygeno.2019.06.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
15 Asai A, Tsuchimoto Y, Ohama H, Fukunishi S, Tsuda Y, Kobayashi M, Higuchi K, Suzuki F. Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC. Oncoimmunology 2017;6:e1299301. [PMID: 28507807 DOI: 10.1080/2162402X.2017.1299301] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]